GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Neuland Laboratories Ltd (NSE:NEULANDLAB) » Definitions » Return-on-Tangible-Equity

Neuland Laboratories (NSE:NEULANDLAB) Return-on-Tangible-Equity : 27.00% (As of Mar. 2024)


View and export this data going back to 2008. Start your Free Trial

What is Neuland Laboratories Return-on-Tangible-Equity?

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Neuland Laboratories's annualized net income for the quarter that ended in Mar. 2024 was ₹2,702 Mil. Neuland Laboratories's average shareholder tangible equity for the quarter that ended in Mar. 2024 was ₹10,008 Mil. Therefore, Neuland Laboratories's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2024 was 27.00%.

The historical rank and industry rank for Neuland Laboratories's Return-on-Tangible-Equity or its related term are showing as below:

NSE:NEULANDLAB' s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 3.83   Med: 13.19   Max: 35.09
Current: 35.09

During the past 13 years, Neuland Laboratories's highest Return-on-Tangible-Equity was 35.09%. The lowest was 3.83%. And the median was 13.19%.

NSE:NEULANDLAB's Return-on-Tangible-Equity is ranked better than
89.6% of 933 companies
in the Drug Manufacturers industry
Industry Median: 6.31 vs NSE:NEULANDLAB: 35.09

Neuland Laboratories Return-on-Tangible-Equity Historical Data

The historical data trend for Neuland Laboratories's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neuland Laboratories Return-on-Tangible-Equity Chart

Neuland Laboratories Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Return-on-Tangible-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.83 17.30 12.01 25.71 35.01

Neuland Laboratories Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Return-on-Tangible-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 47.41 34.70 41.92 38.23 27.00

Competitive Comparison of Neuland Laboratories's Return-on-Tangible-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Neuland Laboratories's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Neuland Laboratories's Return-on-Tangible-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Neuland Laboratories's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where Neuland Laboratories's Return-on-Tangible-Equity falls into.



Neuland Laboratories Return-on-Tangible-Equity Calculation

Neuland Laboratories's annualized Return-on-Tangible-Equity for the fiscal year that ended in Mar. 2024 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: Mar. 2024 )  (A: Mar. 2023 )(A: Mar. 2024 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: Mar. 2024 )  (A: Mar. 2023 )(A: Mar. 2024 )
=3000.789/( (7133.348+10007.857 )/ 2 )
=3000.789/8570.6025
=35.01 %

Neuland Laboratories's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2024 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: Mar. 2024 )  (Q: Dec. 2023 )(Q: Mar. 2024 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: Mar. 2024 )  (Q: Dec. 2023 )(Q: Mar. 2024 )
=2702.476/( (0+10007.857)/ 1 )
=2702.476/10007.857
=27.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Mar. 2024) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.


Neuland Laboratories  (NSE:NEULANDLAB) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.


Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.


Neuland Laboratories Return-on-Tangible-Equity Related Terms

Thank you for viewing the detailed overview of Neuland Laboratories's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Neuland Laboratories (NSE:NEULANDLAB) Business Description

Traded in Other Exchanges
Address
Road No. 82, Jubilee Hills, Plot No. 573A-III, Phoenix IVY Building, 11th Floor (5th Office Level), Hyderabad, TG, IND, 500033
Neuland Laboratories Ltd is a manufacturer of active pharmaceutical ingredients (APIs) and an end-to-end solution provider for the pharmaceutical industry's chemistry needs in Hyderabad. Geographically, it derives a majority of revenue from North America and also has a presence in India, Europe, and Rest of the world.

Neuland Laboratories (NSE:NEULANDLAB) Headlines

No Headlines